



European Monitoring Centre  
for Drugs and Drug Addiction



## PROGRAMME

# Viral hepatitis among people who inject drugs in Europe

Joint meeting between the ECDC European Network for hepatitis B and C surveillance and the EMCDDA expert network on drug-related infectious diseases (DRID)

## 14 June 2017

EMCDDA, Conference Centre, Praça Europa 4, Cais do Sodré, 1249-289 Lisbon, Portugal

### Background and objectives of this joint event

The main reason for convening ECDC and EMCDDA experts to a joint meeting day is to benefit from the diverse expertise and experience across both networks to discuss how Europe can improve its response to hepatitis B and C among people who inject drugs and achieve the targets for elimination set out by the World Health Organization. The joining of the ECDC and EMCDDA networks will prepare the ground for fruitful discussion and exchange around practical evidence-based strategies, for sharing achievements and examples of good practices and for identifying solutions to common challenges.

### 'Lisbon Hepatitis week', 12–16 June 2017 hosted by the EMCDDA


This joint day follows the fourth meeting of the ECDC Hepatitis B and C Network (12-13 June) which will bring together experts from across the EU to discuss how Europe can improve its response to the epidemics of hepatitis B and C, with a particular focus on surveillance.

The joint event is followed by the EMCDDA DRID annual expert meeting, where specialists from across Europe discuss the latest developments in drug-related infectious diseases in Europe, covering the main topic areas of epidemiology, responses and monitoring.

More information:

<http://www.emcdda.europa.eu/expert-meetings/2017/drid>

<http://ecdc.europa.eu/EN/HEALTHTOPICS/VIRAL-HEPATITIS/Pages/viral-hepatitis.aspx>



**Tuesday 13 June 2017**

16.00	<b>Registration</b>
17.00	<p><b>Opening of the EMCDDA/ECDC Joint event</b> Directions for joint thinking towards elimination of hepatitis as a public health threat</p> <p>Alexis Goosdeel, Director of the EMCDDA Piotr Kramarz, Deputy Chief Scientist, ECDC Jean-Luc Sion, Director of the Commission Public Health, country knowledge, crisis management Directorate, European Commission Antons Mozalevskis, Medical Officer, WHO EURO</p>
18.00	Cocktail on the terrace of the European Maritime Safety Agency (above the joint conference centre)

**Wednesday 14 June 2017****Session 1: Hepatitis B and C among people who inject drugs in Europe**

Chairs: Paul Griffiths and Piotr Kramarz

*Session objective: To set the context for the joint meeting of the networks; to provide an overview of national policies and the epidemiology of drug use and hepatitis B and C infection in Europe among people who inject drugs.*

09.00	Hepatitis B and C among people who inject drugs – the current situation and responses, and the challenges for the future (Isabelle Giraudon, EMCDDA)
09.15	Elimination of hepatitis B and C among PWIDs in Europe: implementing the action plan across the continuum of care for PWIDs (Antons Mozalevskis, WHO EURO)
09.30	<p>National HCV policies and PWID</p> <p>a. Update on monitoring national HCV treatment policies in Europe (Stine Nielsen, EMCDDA consultant)</p> <p>b. National strategies, action plans and clinical guidelines on HCV treatment in PWID in 33 European countries: a survey among the Correlation network (Mojca Matičič, Slovenia)</p>
10.00	Panel discussion: reflections on the development of national policies: Magdalena Rosinska (Poland), Hans Blystad (Norway), Jan Fouchard (Denmark) and Mojca Matičič (Slovenia)
10.45	Coffee break

**Session 2: 'Elimination agenda' - indicators for people who inject drugs: developing better information for action**

Chairs: Andrew Amato-Gauci and Isabelle Giraudon

*Session objective: To assess the availability and quality of data for monitoring the health sector responses to viral hepatitis among PWIDs, and identify options for improvement.*

11.15	Critical perspective on the relevant epidemiological indicators and national data for monitoring the health sector response to viral hepatitis among PWIDs (Ruth Zimmermann, Germany)
11.35	Gathering data from European sites on key parameters for projecting HCV prevalence and incidence in PWID (Hannah Fraser, United Kingdom)
11.55	Round table discussion on gaps in current data and the identification of options to address these gaps

12.15	<p>'World Café': EU Projects and Networks relating to PWIDs</p> <p>Introduction by (tbc, CHAFEA)</p> <p>This interactive 'World Café' session will allow participants to learn about current EU projects and networks:</p> <ul style="list-style-type: none"> <li>• HepCare Europe (Jack Lambert)</li> <li>• E-Detect TB (Alistair Story)</li> <li>• HA-REACT (Jeffrey Lazarus)</li> <li>• Correlation network (Eberhard Schatz)</li> </ul> <p>In addition, GAT/In-Mouraria (Ricardo Fuertes and Magda Ferreira) a local harm reduction project, will present their work.</p>
13.30	Lunch break
<p><b>Session 3: 'Elimination agenda': monitoring access of PWID to hepatitis care in Europe: practical national examples</b></p> <p>Chairs: Erika Duffell and Klaudia Palczak</p> <p><i>Session objective: To explore the key opportunities and barriers to hepatitis C care among PWID.</i></p>	
14.30	Country presentation: Access to HCV treatment for PWID in Portugal, Ricardo Baptista Leite (Member of Parliament, Head of Public Health, Catolica University of Portugal)
15.00	HCV treatment for PWID in Europe: the perspective of EASL (Helena Cortez-Pinto, EASL – European Association for the study of the liver)
15.20	Short discussion on monitoring access to treatment and questions to the speakers
15.30	Coffee break
<p><b>Session 4: Hepatitis B and C in the prison population</b></p> <p>Chairs: Erika Duffell and Dagmar Hedrich</p> <p><i>Session objective: To explore the key issues and the opportunities for tackling hepatitis B and C more effectively among the prison population in Europe</i></p>	
16.00	Drug use, viral hepatitis and harm reduction in the prison setting: opportunities and challenges (Linda Montanari, EMCDDA)
16.15	Hepatitis B and C in the prison population in Europe: development of European guidance (Lara Tavoschi, ECDC)
16.30	High recurrence rate of hepatitis C infection after treatment in prison inmates in Luxembourg (Carole Devaux, Luxembourg)
16.45	Short discussion and questions to the speakers
<p><b>Final debate</b></p> <p>Chairs: Paul Griffiths and Piotr Kramarz</p> <p><i>Final debate covering conclusions of the previous sessions and reflection on what can be done better to tackle the hepatitis epidemic among people who inject drugs.</i></p>	
16.50	<p>Lúis Mendão (Civil Society Forum HIV, hepatitis and TB)</p> <p>Helena Cortez-Pinto (Gastroenterologist in Centro Hospitalar Lisboa Norte, Lisbon, and EU Policy Councillor of EASL)</p> <p>Danijela Simic (Head of Department for HIV infection, STI, viral hepatitis and tuberculosis, Centre for Prevention and Control of Diseases of the Institute of Public Health of Serbia "Dr Milan Jovanovic Batut")</p> <p>Tatiana Reic (European Liver Patients Associations ELPA)</p>
17.30	Concluding remarks (Paul Griffiths and Piotr Kramarz)
18.00	End of the joint ECDC-EMCDDA meeting

The EMCDDA DRID expert meeting starts on Thursday 15 June, 09.00.